Because of the high incidence of SOD1 mutations, which accounts for 20–25% of fALS cases, which represents 1 to 2% of all ALS cases, SOD1 is regarded as the most comprehensively studied gene and is one of the prime targets to find therapeutic options for treatment of ALS [155]. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.